Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 57 entries
View as:

French Observational Study of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Real-World Settings

Phase: N/A Priority: Normal
NCT ID: NCT05590702 Org: User:
Start: 11/11/22 End: 12/01/32 Due: 12/01/33

Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT03609060 Org: User:
Start: 08/24/18 End: 12/31/25 Due: 12/31/26

Treatment of Localized Low Grade Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT00536458 Org: User:
Start: 03/31/99 End: 12/31/06 Due: 12/31/07

Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01455025 Org: User:
Start: 01/31/12 End: 08/31/15 Due: 08/31/16

Phase I Study in RAD 001 Patients With Relapse AML

Phase: N/A Priority: Normal
NCT ID: NCT01074086 Org: User:
Start: 02/29/08 End: 12/31/12 Due: 12/31/13

BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Phase: N/A Priority: Normal
NCT ID: NCT03931642 Org: User:
Start: 07/05/19 End: 10/21/22 Due: 10/21/23

GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00896519 Org: User:
Start: 03/31/09 End: - Due: -

GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly

Phase: N/A Priority: Normal
NCT ID: NCT00925873 Org: User:
Start: 06/30/96 End: 11/30/04 Due: 11/30/05

Treatment of Disseminated High Grade Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00536393 Org: User:
Start: 10/31/00 End: 10/31/04 Due: 10/31/05

Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)

Phase: N/A Priority: Normal
NCT ID: NCT01301820 Org: User:
Start: 01/31/11 End: 02/28/13 Due: 02/28/14

Liposomal Anthracyclin in the Treatment of Elderly ALL

Phase: N/A Priority: Normal
NCT ID: NCT00600977 Org: User:
Start: 03/31/02 End: 10/31/06 Due: 10/31/07

Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00740415 Org: User:
Start: 06/30/07 End: 08/31/15 Due: 08/31/16

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00920153 Org: User:
Start: 05/31/08 End: 03/31/16 Due: 03/31/17

High-Dose Therapy Treatment in Patients With Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00696735 Org: User:
Start: 06/30/94 End: 05/31/06 Due: 05/31/07

JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT01795677 Org: User:
Start: 12/31/12 End: 03/31/19 Due: 03/31/20

Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL

Phase: N/A Priority: Normal
NCT ID: NCT01612988 Org: User:
Start: 07/31/12 End: 04/30/18 Due: 04/30/19

Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT00842595 Org: User:
Start: 12/31/03 End: 05/31/10 Due: 05/31/11

Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT00869284 Org: User:
Start: 10/31/94 End: 02/28/09 Due: 02/28/10

Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III

Phase: N/A Priority: Normal
NCT ID: NCT00483132 Org: User:
Start: 09/30/94 End: 04/30/02 Due: 04/30/03

Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04010968 Org: User:
Start: 09/27/19 End: 01/30/25 Due: 01/30/26

Phase III Study Treatment of CLL B and C

Phase: N/A Priority: Normal
NCT ID: NCT00535912 Org: User:
Start: 01/31/99 End: 03/31/06 Due: 03/31/07

REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05621148 Org: User:
Start: 01/25/23 End: 03/31/24 Due: 03/31/25

Study of Mantle Cell Lymphoma Treatment by RiBVD

Phase: N/A Priority: Normal
NCT ID: NCT01457144 Org: User:
Start: 10/31/11 End: 03/31/16 Due: 03/31/17

COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias

Phase: N/A Priority: Normal
NCT ID: NCT04416438 Org: User:
Start: 05/18/20 End: 09/01/22 Due: 09/01/23

Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years

Phase: N/A Priority: Normal
NCT ID: NCT00285389 Org: User:
Start: 02/28/02 End: 12/31/08 Due: 12/31/09